NeurAxis Participates in Lytham Partners Fall 2026 Investor Conference

CARMEL, Ind., Sept. 16, 2026 /CourierPR/ -- NeurAxis, Inc., a medical technology company specializing in neuromodulation therapies for chronic conditions, will participate in the Lytham Partners Fall 2026 Investor Conference. The event, scheduled for September 29-30, 2026, will feature a webcast presentation and one-on-one meetings with investors.

The webcast, set for 11:45 a.m. ET on Tuesday, September 29, will be accessible via the conference website at lythampartners.com/fall2026 or directly at app.webinar.net/lJ5aBmzWwkZ. The presentation will provide an overview of NeurAxis's initiatives and progress, including its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, which is FDA-cleared for treating functional abdominal pain in irritable bowel syndrome (IBS) and functional dyspepsia.

NeurAxis, Inc., founded to advance science and evidence-based medicine, is dedicated to expanding the adoption of its IB-Stim technology. This therapy is designed to address chronic and debilitating conditions in both children and adults. The company is currently conducting additional clinical trials of PENFS in various pediatric and adult conditions, aiming to address large unmet healthcare needs.

The participation in the Lytham Partners Fall 2026 Investor Conference underscores NeurAxis's commitment to engaging with the investment community and sharing its progress. The company's focus on innovative neuromodulation therapies positions it as a key player in the medical technology sector, with ongoing efforts to improve patient outcomes through advanced medical solutions.